Akshat Jain Explores a New Blood Journals Study on the Bleeding Burden in Type 1 VWD
Akshat Jain, Hematology Pediatric Workforce Task Force at American Society of Hematology, shared on LinkedIn:
”Novel Bispecific Nanobody
New study out in Blood Journals Portfolio on addressing the bleeding burden in Type 1 VWD patients and development of novel therapy options for these patients via SubCutanous route!
American Society of Hematology
KB-V13A12 is designed to increase the patient’s own von Willebrand factor (VWF) levels by bridging VWF to albumin, potentially enhancing VWF survival in the bloodstream.
KB-V13A12 is a bispecific nanobody that binds both VWF and albumin, aiming to harness the recycling pathway of albumin to protect and maintain higher circulating VWF levels.
In laboratory experiments, the nanobody efficiently tethered VWF to albumin without interfering with VWF’s ability to bind Factor VIII or function in clot formation.
In VWD type 1 mouse models, a single subcutaneous dose of KB-V13A12 led to a rapid, dose-dependent increase in VWF levels—up to 2.1-fold—for up to two weeks.
This elevation translated to significantly improved bleeding control in treated mice, using established bleeding models.”
Read the full article in Blood.
Article: A bispecific nanobody for the treatment of von Willebrand disease type 1
Authors: Ivan Peyron, Caterina Casari, Geneviève McCluskey, Vincent Licari, Emilie Bocquet, Claire Auditeau, Mélanie Y. Daniel, Stéphanie Roullet, Sophie Susen, Olivier D. Christophe, Peter J. Lenting, Cécile V. Denis
Stay updated on all scientific advances with Hemostasis Today.
-
Jan 5, 2026, 15:33Mona Ahmed on Why Some Calcified Nodules Trigger ACS and Others Do Not
-
Jan 5, 2026, 14:17Abdul Mannan – VWF:RCo for Diagnosing von Willebrand Disease: That Test Might Be Failing Your Patients
-
Jan 5, 2026, 13:57Ewang Yemi: CAD is Real and Dangerous – Keep Your Heart Beating
-
Jan 5, 2026, 13:42Dr. Martha Boeckenfeld Shares VetiGel Creation Experiment: How A 17-Year-Old Mixed Algae in a Small Hidden Lab
-
Jan 5, 2026, 12:55Chokri Ben Lamine Explains Washed PRBCs!
-
Jan 5, 2026, 12:30ASH: Be Part of The Next Cohort of Hematology Quality Improvement Leaders
-
Jan 5, 2026, 09:59WFH Released New Evidence-Based Guidelines on AAV Gene Therapy for Hemophilia
-
Jan 5, 2026, 09:51Pete Stibbs: We Still Tend to Talk About VTE Like It’s a Plumbing Problem
-
Jan 5, 2026, 09:40Christopher Pittman on Treating Varicose Veins Before Knee or Hip Replacement